Dr Liam Fernyhough

Hock, B. D., Macpherson, S. A., Fernyhough, L. J., & McKenzie, J. L. (2014). Chronic lymphocytic leukemia cells become both activated and immunosuppressive following interaction with CD3 and CD28 stimulated PBMC. Leukemia Research, 38(10), 1217-1223. doi: 10.1016/j.leukres.2014.06.004

Journal - Research Article

Fernyhough, L. J., Buchan, V. A., McArthur, L. T., & Hock, B. D. (2013). Relative recovery of haematopoietic stem cell products after cryogenic storage of up to 19 years. Bone Marrow Transplantation, 48(1), 32-35. doi: 10.1038/bmt.2012.97

Journal - Research Article

Fernyhough, L. J., Hock, B. D., Taylor, J., Pearson, J., & Ganly, P. (2013). Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: A retrospective study at a single New Zealand centre. Internal Medicine Journal, 43(2), 130-137. doi: 10.1111/j.1445-5994.2012.02819.x

Journal - Research Article

Hock, B. D., Fernyhough, L. J., Gough, S. M., & McKenzie, J. L. (2013). Clinical significance of plasma levels of soluble CD40 in patients with chronic lymphocytic leukemia. Open Journal of Blood Diseases, 3(1), 1-5. doi: 10.4236/ojbd.2013.31001

Journal - Research Article

Zhang, M., Moore, G. A., Fernyhough, L. J., Barclay, M. L., & Begg, E. J. (2012). Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry. Analytical & Bioanalytical Chemistry, 404(6-7), 2091-2096. doi: 10.1007/s00216-012-6284-0

Journal - Research Article

Geertsema, L., Lucas, S. J. E., Cotter, J. D., Hock, B., McKenzie, J., & Fernyhough, L. J. (2011). The cardiovascular risk factor, soluble CD40 ligand (CD154), but not soluble CD40, is lowered by ultra-endurance exercise in athletes. British Journal of Sports Medicine, 45(1), 42-45. doi: 10.1136/bjsm.2008.051896

Journal - Research Article

Hock, B. D., McKenzie, J. L., McArthur, L., Tansley, S., Taylor, K. G., & Fernyhough, L. J. (2010). CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: Patient survival in comparison to age and sex matched population data. Internal Medicine Journal, 40(12), 842-849. doi: 10.1111/j.1445-5994.2009.02135.x

Journal - Research Article

Hock, B. D., Fernyhough, L. J., Gough, S. M., Steinkasserer, A., Cox, A. G., & McKenzie, J. L. (2009). Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia. Leukemia Research, 33(8), 1089-1095. doi: 10.1016/j.leukres.2009.01.001

Journal - Research Article

Fernyhough, L. J., Romeril, K., Carter, J., & Ritchie, D. S. (2005). Marrow fibrosis and pure red cell aplasia complicating early stage chronic lymphocytic leukaemia. Pathology, 37(2), 186-187.

Journal - Research Article

Trengrove, A. M., Schouten, J. E., & Fernyhough, L. (2012). Comparing pegylated and conventional G-CSF in the mobilisation of PBSC in patients with myeloma. Biology of Blood & Marrow Transplantation, 18(Suppl. 2), (pp. S384-S385). doi: 10.1016/j.bbmt.2011.12.491

Conference Contribution - Published proceedings: Abstract

Quach, H., Fernyhough, L. J., Henderson, R., Corbett, G. M., Honemann, D., Peinert, S., … Prince, M. (2011). A comparison of the efficacy and safety of low-dose lenalidomide plus low-dose dexamethasone (RD) with full-dose lenalidomide + dexamethasone (RD) in patients (PTs) with relapsed/refractory multiple myeloma (RRMM). Proceedings of the 13th International Myeloma Workshop (IMW). Retrieved from http://www.myeloma-paris2011.com/content/view/21/12/

Conference Contribution - Published proceedings: Abstract

Taylor, J., Fernyhough, L., Hock, B., & Ganly, P. (2011). Multiple myeloma patients treated in Christchurch, New Zealand: A retrospective analysis. Proceedings of the Inaugural International Cancer Symposium. Retrieved from http://www.wnmeds.ac.nz/cancersymposium/programme.html

Conference Contribution - Published proceedings: Abstract

Quach, H., Fernyhough, L., Henderson, R., Corbett, G., Lynch, K., Ritchie, D., … Prince, H. M. (2010). Lower-dose lenalidomide and dexamethasone reduces toxicity without compromising efficacy in patients with relapsed/refractory myeloma, who are aged ≥60 years or have renal impairment: Planned interim results of a Prospective Multicentre Phase II Trial. Proceedings of the 52nd American Society of Hematology (ASH)^® Annual Meeting and Exposition. Retrieved from http://ash.confex.com/ash/2010/webprogram/Paper32912.html

Conference Contribution - Published proceedings: Abstract

Fernyhough, L., Tsai, J., & Spearing, R. (2006). Evans Syndrome with durable response to Rituximab. Proceedings of the Haematology Society of Australia & New Zealand (HSANZ) Annual Scientific Meeting. Retrieved from http://www.hsanz.org.au/resources/abstracts.cfm

Conference Contribution - Published proceedings: Abstract

Merriman, E., Patton, N., Fernyhough, L., & Ganly, P. (2006). Two cases of granulocytic sarcoma. Proceedings of the Haematology Society of Australia & New Zealand (HSANZ) Annual Scientific Meeting. Retrieved from http://www.hsanz.org.au/resources/abstracts.cfm

Conference Contribution - Published proceedings: Abstract

Fernyhough, L., Ebbett, A., Sanders, J., Spearing, R., Gibbons, S., Ganly, P., … Patton, N. (2005, October). Tandem high dose melphalan (HDM) and HLA identical-sibling allogeneic non myeloablative stem cell transplant (NMAT SCT) for multiple myeloma: A single centre experience. Poster session presented at the HSANZ/ANZSBT/ASTH Annual Scientific Meeting, Sydney, Australia.

Conference Contribution - Poster Presentation (not in published proceedings)